Continuous Intraventricular Interferon Alpha Infusion in Pediatric SSPE

Overview

This report describes a surgical technique for continuous intraventricular infusion of interferon alpha (α-IFN) using a rechargeable pump in children with subacute sclerosing panencephalitis (SSPE). The approach aims to maintain constant cerebral drug levels, potentially stabilizing neurological decline in this rare, progressive disease.

Background

SSPE is a rare, progressive neurodegenerative disorder caused by persistent measles virus infection, characterized by motor and cognitive decline leading to severe disability and death. Diagnosis relies on clinical criteria and supportive findings such as elevated measles antibodies in CSF and serum. Current treatments are limited, with intrathecal α-IFN showing promise. Continuous intraventricular delivery via an implanted pump offers a novel method to maintain steady drug concentrations and reduce toxicity.

Data Highlights

A 5-year-old male with SSPE underwent surgical implantation of a rechargeable pump delivering continuous intraventricular α-IFN at 0.5 ml/day (250,000 I.U. daily). The pump reservoir is refilled approximately every 21 days with 9,000,000 I.U. of α-IFN. MRI and EEG findings demonstrated progressive brain involvement and epileptiform activity prior to treatment initiation.

Key Findings

• SSPE diagnosis was confirmed by clinical presentation, MRI changes, EEG abnormalities, and elevated measles antibodies in CSF and serum.
• A surgical technique was developed for implanting a ventricular catheter connected to a subcutaneous rechargeable pump for continuous α-IFN infusion.
• Neuronavigation and endoscopic assistance facilitate accurate catheter placement into the third ventricle via the foramen of Monro.
• The pump allows continuous drug delivery, maintaining stable cerebral drug concentrations and reducing medication toxicity.
• The device is refilled every 21 days with a high dose of α-IFN, supporting potential long-term treatment.
• Early initiation of this therapy may help stabilize neurological decline in SSPE, although data on long-term outcomes remain limited.

Clinical Implications

This continuous intraventricular α-IFN infusion technique provides a promising therapeutic option for SSPE, enabling steady drug delivery and potentially improving disease stabilization. Careful patient selection and multidisciplinary management are essential. The approach requires surgical expertise in pediatric neuroanatomy and device implantation.

Conclusion

Continuous intraventricular infusion of interferon alpha via a rechargeable pump represents a feasible and innovative treatment modality for children with SSPE, potentially improving clinical outcomes by maintaining consistent drug levels in the CNS. Further studies are needed to evaluate long-term efficacy and safety.

References

1. Original Article -- Administering Continuous Intraventricular Interferon Alpha Infusion in Children with Subacute Sclerosing Panencephalitis